Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Annamycin + Cytarabine in AML
NCT05319587Phase 2Completed
- Sponsor
- Moleculin Biotech, Inc.
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of annamycin in acute myeloid leukemia (AML), sponsored by Moleculin Biotech, Inc.. Started Sep 2022; status: completed.
02
Drugs
annamycin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05319587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319587.